Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Microbicides news

Show

From To
IPM receives multi-year award from UK government to advance technologies for women's HIV

The nonprofit International Partnership for Microbicides (IPM) announced today that it has received a £12 million (US$15.6 million) award over four years from the United Kingdom government through the Department for International Development to advance promising HIV and multipurpose prevention products that women could use to protect their sexual and reproductive health.

Published
20 July 2017
From
Eurekalert Medicine & Health
Men often control use of women’s HIV prophylactic gel in Zambia

In Zambia, men often control the use of a microbicide gel that is meant to give women autonomy in preventing HIV infection, according to researchers. Use of the vaginal gel, which is now in phase 3 trials, is limited by social norms that entrench male dominance, they wrote in Global Public Health.

Published
17 July 2017
From
Healio
IPM's dapivirine vaginal ring now under review by European Medicines Agency

The nonprofit International Partnership for Microbicides (IPM) is pleased to announce that its application for the monthly dapivirine vaginal ring, designed to reduce the risk of HIV-1 infection via vaginal intercourse in HIV-negative women in combination with safer sex practices, has been validated and is now under review by the European Medicines Agency (EMA).

Published
14 July 2017
From
Eurekalert Medicine & Health
Women’s bacteria thwarted attempt at anti-HIV vaginal gel

Creating new HIV prevention tools for women has proven frustratingly slow and researchers have found another hurdle: bacteria in the reproductive tract.

Published
02 June 2017
From
STAT
IPM Advances Three-month HIV Prevention and Contraception Ring to Clinical Trial

The three-month vaginal ring is designed to slowly — and simultaneously — release the antiretroviral drug dapivirine to prevent HIV and the contraceptive hormone levonorgestrel. The primary goal of the study, known as MTN-030/IPM 041, is to assess the ring’s safety and pharmacokinetics (how the body processes the two drugs). Results of the trial, including the product’s acceptability to women and their willingness to use it in the future, will inform next steps for the ring’s formulation and future trial designs.

Published
03 May 2017
From
International Partnership for Microbicides
MTN begins first trial of new dapivirine ring with both anti-HIV drug and contraceptive

Researchers hoping for a single product to protect against both HIV and unintended pregnancy took an important step toward realizing their goal with the start of a trial of a vaginal ring containing the antiretroviral drug dapivirine and a hormonal contraceptive. A dapivirine-only ring that women use a month at a time was safe and helped prevent HIV in two large trials. The new ring adds levonorgestrel and could be used for three months.

Published
03 May 2017
From
Eurekalert Medicine & Health
Bacterial vaginosis does not affect efficacy of oral PrEP in women

Research presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2017) found that the efficacy of oral pre-exposure prophylaxis (PrEP) for women was not affected

Published
23 February 2017
By
Gus Cairns
Vaginal Ring Form of PrEP Does Not Reduce Contraceptive Effectiveness

The antiretroviral (ARV)-containing vaginal ring form of pre-exposure prophylaxis (PrEP) that reduced HIV risk in a major trial does not lower the effectiveness of hormonal birth control. This finding assuages concerns raised by previous research that the non-nucleoside reverse transcriptase inhibitor (NNRTI) class of ARVs has been associated with a lowered effectiveness of some hormonal contraceptives.

Published
16 February 2017
From
Poz
New HIV prevention products will need marketing and effective health services to reach the people who need them

There is a naivety among many HIV prevention researchers and advocates about the steps needed to introduce and implement new HIV prevention technologies such as oral pre-exposure

Published
24 October 2016
By
Roger Pebody
New microbicide enema achieves high levels of drug in rectal tissues in monkeys

Rectal microbicides that protect against HIV transmission via anal sex are a bigger technical challenge than vaginal ones. The rectal lining is more delicate than the vaginal, so

Published
22 October 2016
By
Gus Cairns
← First12345...24Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.